The OxyContin debate has been part of a larger fight in which patient advocacy groups that are worried about historic undertreatment of pain have joined with drug companies to argue against regulatory and law enforcement restrictions on painkillers that might unduly restrict their availability.
Giuliani was a key ally in that debate. He cast himself as an expert because of his prosecutorial background and his experience with prostate cancer. As part of his work for Purdue, he agreed to chair a group called the Rx Action Alliance, which promoted a "balanced" approach that would address abuse but maintain access for patientsâ¦
As the DEA continues its misguided war on pain management specialists, it's really quite refreshing to know that a front-running presidential candidate understands the problem. DEA's overreaction to OxyContin abuse has been disastrous, resulting in the reluctance of doctors nationwide to prescribe pain-relievers to deserving patients. Whether it was his prostate cancer, or the money Purdue paid his firm, something has led him to stand up for patient access and there's nothing wrong with that.
The only remaining question is why Giuliani is so hostile to medical marijuana. The fact pattern is remarkably similar: the stigma resulting from widespread recreational marijuana use has created a climate in which legitimate patients are denied medical access to the drug.
If only medical marijuana patients could afford to hire Giuliani Partners, LLC to help improve their public imageâ¦
(This blog post was published by StoptheDrugWar.org's lobbying arm, the Drug Reform Coordination Network, which also shares the cost of maintaining this web site. DRCNet Foundation takes no positions on candidates for public office, in compliance with section 501(c)(3) of the Internal Revenue Code, and does not pay for reporting that could be interpreted or misinterpreted as doing so.)